Home » Stocks » ILMN

Illumina, Inc. (ILMN)

Stock Price: $398.85 USD -0.76 (-0.19%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $399.00 +0.15 (0.04%) Mar 5, 7:21 PM
Market Cap 58.19B
Revenue (ttm) 3.24B
Net Income (ttm) 656.00M
Shares Out 147.00M
EPS (ttm) 4.45
PE Ratio 89.63
Forward PE 75.19
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $398.85
Previous Close $399.61
Change ($) -0.76
Change (%) -0.19%
Day's Open 402.24
Day's Range 382.41 - 403.48
Day's Volume 1,181,764
52-Week Range 196.78 - 555.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 day ago

Illumina (ILMN) closed the most recent trading day at $398.85, moving -0.19% from the previous trading session.

Business Wire - 1 day ago

SAN DIEGO--(BUSINESS WIRE)--Illumina and R-Pharm received medical device registration in Russia of the NextSeq 550Dx platform and reagent kits as well as MiSeq Dx reagents

24/7 Wall Street - 3 days ago

With the trading day about halfway over, the broad markets have not made up their minds on a direction for the day.

Other stocks mentioned: MSFT, ORCL, SPCE, TSLA, ADPT, CTXS, DHR, DOCU
GuruFocus - 1 week ago

Generation Investment Management, the firm co-founded by Al Gore (Trades, Portfolio) and David Blood, disclosed this month that its top four buys during the fourth quarter of 2020 included a n...

Other stocks mentioned: BABA, BAX, EFX
Investors Business Daily - 1 week ago

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Other stocks mentioned: AZN, BNTX, GILD, GSK, JNJ, LLY, MRNA, NVAX, PACB, PFE, REGN, TMO, VIR
PRNewsWire - 1 week ago

SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- A judge in the U.S. District Court for the Northern District of California has granted MGI's motion for leave to amend to add a new inequitable con...

Business Wire - 2 weeks ago

TÜBINGEN, Germany--(BUSINESS WIRE)--Illumina partners with the University of Tubingen to study the value of whole-genome sequencing as a diagnostic for patients with genetic diseases

Zacks Investment Research - 2 weeks ago

CHRS vs. ILMN: Which Stock Is the Better Value Option?

Other stocks mentioned: CHRS
Bloomberg Technology - 2 weeks ago

A 'Bio Force' Is Needed to Stop Virus, Says Illumina CEO

Feb.17 -- Illumina chief executive officer Francis deSouza discusses the company's impressive start to the year and why a "bio force" is needed post pandemic to ensure viruses don't wreak furt...

Zacks Investment Research - 2 weeks ago

Seasonality in DTC functionality also continues to erode Illumina's (ILMN) microarray sales.

ETF Trends - 3 weeks ago

Biotechnology sector-related exchange traded funds strengthened after Illumina (NasdaqGS: ILMN) announced better-than-expected quarterly earnings and an optimistic 2021 outlook. On Friday, the...

The Motley Fool - 3 weeks ago

Even as markets took a pause, there's still plenty of action in individual stock names.

Other stocks mentioned: COHR
Investors Business Daily - 3 weeks ago

Illumina stock rocketed to a record Friday after the company boosted its first quarter outlook on the growing need for DNA sequencing to surveil Covid-19 mutations and vaccines. The post Illum...

The Motley Fool - 3 weeks ago

The genomic sequencing pioneer reported great fourth-quarter results.

Zacks Investment Research - 3 weeks ago

Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.

CNBC Television - 3 weeks ago

Illumina CEO on the hunt to find Covid-19 variants

Francis deSouza, CEO of Illumina, joins CNBC's Meg Tirrell to discuss the company's earnings and business into Covid-19 sequencing.

Zacks Investment Research - 3 weeks ago

Illumina (ILMN) delivered earnings and revenue surprises of 0.83% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 weeks ago

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Q4&FY 2020 Earnings Release

Benzinga - 3 weeks ago

Illumina (NASDAQ:ILMN) will be releasing its next round of earnings this Thursday, February 11. For all of the relevant information, here is your guide for Thursday's Q4 earnings announcement.

Business Wire - 3 weeks ago

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--SVB Leerink & Cowen Annual Global Healthcare Conferences Webcasting

Zacks Investment Research - 3 weeks ago

Illumina (ILMN) is likely to have gained during the fourth quarter from the robust performance of sequencing consumable segment.

Business Wire - 3 weeks ago

SAN DIEGO--(BUSINESS WIRE)--Illumina has selected nine new genomics companies for the second global funding cycle of Illumina Accelerator.

The Motley Fool - 3 weeks ago

The genomics leader got a boost from identifying new COVID variants, and won a patent lawsuit.

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Illumina announced support for national pilot study in Belgium to evaluate impact of comprehensive genomic profiling for late stage cancer.

Zacks Investment Research - 1 month ago

Illumina (ILMN) partners with Sequoia Capital China to set up a genomics-focused startup incubator in China.

The Motley Fool - 1 month ago

Analysts' pessimism about these stocks appears to be off-base.

Other stocks mentioned: FLGT
Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Illumina and Sequoia Capital will collaborate to build an ecosystem for life science startup companies advancing breakthrough applications in genomics

Forbes - 1 month ago

Illumina, best known for its genetic variation and biological function systems, has gained 9.5% over the last 5 trading days, after a UK court announced a judgment in Illumina's favor in a pat...

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Q4&FY 2020 Earnings Date Announcement

Zacks Investment Research - 1 month ago

Bear of the Day: Illumina (ILMN)

CNBC Television - 1 month ago

'Chances are high' the South African Covid-19 variant is in the U.S.: Illumina CEO

The CEO of the largest maker of genome sequencing equipment, Francis deSouza, told CNBC's "Squawk Box" Friday that the United States only sequences 0.3% of positive cases of Covid-19. He added...

Zacks Investment Research - 1 month ago

Illumina (ILMN) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced that the High Court of Justice, Chancery Division, Patents Court, issued a judgment in its favor in the patent infring...

CNBC Television - 1 month ago

Final Trades: ILMN, EQIX, BFT & XLF

The Fast Money traders offer their final trades of the week.

Other stocks mentioned: XLF, BFT, EQIX
The Motley Fool - 1 month ago

Buy these three biotech stocks before they take off.

Other stocks mentioned: AMGN, TRIL
Zacks Investment Research - 1 month ago

Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.

Other stocks mentioned: MYGN
Seeking Alpha - 1 month ago

Illumina, Inc. (ILMN) CEO Francis deSouza Presents at J.P. Morgan 39th Annual Healthcare Conference (Transcript)

CNBC Television - 1 month ago

Illumina CEO on 2021 outlook and tracking new coronavirus strains

Illumina CEO Francis Desouza joins 'Closing Bell' to discuss the company's guidance, tracking the new covid strains and the company's 2020 outlook.

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) is transforming genomic data bottlenecks into catalysts with the launch of Illumina Connected Analytics (ICA). This new and integrated...

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio of new and expanded oncology partnerships...

Zacks Investment Research - 1 month ago

Illumina (ILMN) collaborates with Helix with support from the CDC to set up an enhanced surveillance infrastructure to track the emergence and prevalence of B.1.1.7.

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevale...

Investopedia - 2 months ago

Due to lucrative risk/reward setups and heightened fundamental demand, many active traders will be watching biotech stocks.

Other stocks mentioned: IBB, MRNA
Zacks Investment Research - 2 months ago

Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and worldwide expansion to drive growth.

Schaeffers Research - 2 months ago

The shares of Illumina Inc. (NASDAQ:ILMN) are up 3.2% at $374.30 at last check, after the biotechnology concern received an upgrade from Piper Sandler to "overweight" from "neutral," as well a...

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to part...

InvestorPlace - 2 months ago

True, there are political risks in the industry. But there are also lots of growth opportunities for investors in healthcare stocks.

Other stocks mentioned: ARE, CERN, ISRG, PFE, TDOC, ZTS
InvestorPlace - 2 months ago

These big data stocks are the needle-movers of the industry and will leverage big data to make our lives easier and much more informed. The post 7 Big Data Stocks That Are Feeding Our Informat...

Other stocks mentioned: IBM, MSFT, PLTR, SAP, SPLK, CRM
Zacks Investment Research - 2 months ago

Illumina (ILMN) signs agreement to expand the availability of WGS to enable faster and cost-effective diagnosis of genetic diseases in children.

Business Wire - 2 months ago

SAN DIEGO & WELLESLEY, Mass.--(BUSINESS WIRE)--Illumina and Harvard Pilgrim Health Care expand access to whole-genome sequencing for genetic disease testing.

About ILMN

Illumina provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 28, 2000
CEO
Jay Flatley
Employees
7,800
Stock Exchange
NASDAQ
Ticker Symbol
ILMN
Full Company Profile

Financial Performance

In 2020, Illumina's revenue was $3.24 billion, a decrease of -8.58% compared to the previous year's $3.54 billion. Earnings were $656.00 million, a decrease of -34.53%.

Financial Statements

Analyst Forecasts

According to 18 analysts, the average rating for Illumina stock is "Hold." The 12-month stock price forecast is 408.13, which is an increase of 2.33% from the latest price.

Price Target
$408.13
(2.33% upside)
Analyst Consensus: Hold